{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:01:18Z","timestamp":1788588078027,"version":"build-2803163510"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Targeted radionuclide therapy (TRT) is based on injections of cancer-specific molecules conjugated with radioactive nuclides. Despite the specificity of this treatment, it is not devoid of side effects limiting its use and is especially harmful for rapidly proliferating organs well perfused by blood, like bone marrow. Optimization of radioconjugate administration accounting for toxicity constraints can increase treatment efficacy. Based on our experiments on a disseminated multiple myeloma mouse model treated by 225Ac-DOTA-daratumumab, we developed a mathematical model, investigation of which highlighted the following principles for optimization of TRT: (i) Nuclide-to-antibody ratio importance. The density of radioconjugates on cancer cells determines the density of radiation energy deposited in them. A low labeling ratio as well as accumulation of unlabeled antibodies and antibodies attached to decay products in the bloodstream can mitigate cancer radiation damage due to excessive occupation of specific receptors by antibodies devoid of radioactive nuclides. (ii) Cancer-binding capacity\u2013based dosing. The total number of specific receptors on cancer cells is a critical factor for treatment optimization, and its estimation may allow increasing treatment efficacy close to its theoretical limit. Injection of doses significantly exceeding cancer-binding capacity should be avoided because radioconjugates remaining in the bloodstream have a negligible efficacy-to-toxicity ratio. (iii) Particle range\u2013guided multi-dosing. The use of short-range particle emitters and high-affinity antibodies can allow for robust treatment optimization via initial saturation of cancer-binding capacity, enabling redistribution of further injected radioconjugates and deposited doses toward still viable cells that continue expressing specific receptors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Mathematical modeling yields general principles for optimization of TRT in mouse models of multiple myeloma that can be extrapolated to other cancer models and clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0306","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:04:51Z","timestamp":1730109891000},"page":"2955-2967","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-9002","authenticated-orcid":false,"given":"Maxim","family":"Kuznetsov","sequence":"first","affiliation":[{"name":"1Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9747-4349","authenticated-orcid":false,"given":"Vikram","family":"Adhikarla","sequence":"additional","affiliation":[{"name":"1Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0255-0468","authenticated-orcid":false,"given":"Enrico","family":"Caserta","sequence":"additional","affiliation":[{"name":"2Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-4327","authenticated-orcid":false,"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7763-770X","authenticated-orcid":false,"given":"John E.","family":"Shively","sequence":"additional","affiliation":[{"name":"4Department of Immunology and Theranostics, Beckman Research Institute, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-6891","authenticated-orcid":false,"given":"Flavia","family":"Pichiorri","sequence":"additional","affiliation":[{"name":"2Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-159X","authenticated-orcid":false,"given":"Russell C.","family":"Rockne","sequence":"additional","affiliation":[{"name":"1Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"2026031614575620500_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","article-title":"Advances in antibody-based therapy in oncology","volume":"4","author":"Zinn","year":"2023","journal-title":"Nat Cancer"},{"key":"2026031614575620500_bib2","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","journal-title":"Lancet"},{"key":"2026031614575620500_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/2040620715572295","article-title":"Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development","volume":"6","author":"Phipps","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"2026031614575620500_bib4","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.2147\/CMAR.S212526","article-title":"Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy","volume":"12","author":"Dima","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2026031614575620500_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"2026031614575620500_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"key":"2026031614575620500_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2022.08.010","article-title":"A primer on radiopharmaceutical therapy","volume":"115","author":"Salerno","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 3","key":"2026031614575620500_bib8","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J Nucl Med"},{"key":"2026031614575620500_bib9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","article-title":"EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry","volume":"37","author":"Hindorf","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026031614575620500_bib10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.120.251983","article-title":"Comparison of CD38-targeted \u03b1-versus \u03b2-radionuclide therapy of disseminated multiple myeloma in an animal model","volume":"62","author":"Minnix","year":"2021","journal-title":"J Nucl Med"},{"key":"2026031614575620500_bib11","doi-asserted-by":"crossref","first-page":"1607673","DOI":"10.1080\/2162402X.2019.1607673","article-title":"Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors","volume":"8","author":"Dawicki","year":"2019","journal-title":"Oncoimmunology"},{"key":"2026031614575620500_bib12","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1182\/bloodadvances.2020002603","article-title":"Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64\u2013labeled daratumumab","volume":"4","author":"Krishnan","year":"2020","journal-title":"Blood Adv"},{"key":"2026031614575620500_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plrev.2021.10.001","article-title":"Improving cancer treatments via dynamical biophysical models","volume":"39","author":"Kuznetsov","year":"2021","journal-title":"Phys Life Rev"},{"key":"2026031614575620500_bib14","first-page":"51","article-title":"In silico clinical trials: is it possible?","volume-title":"High performance computing for drug discovery and biomedicine","author":"Arsene","year":"2023"},{"key":"2026031614575620500_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s44222-023-00089-7","article-title":"Computational approaches to modelling and optimizing cancer treatment","volume":"1","author":"McDonald","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"2026031614575620500_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fphar.2020.00997","article-title":"Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges","volume":"11","author":"Zou","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026031614575620500_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2307\/3579648","article-title":"The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships","volume":"150","author":"Brenner","year":"1998","journal-title":"Radiat Res"},{"key":"2026031614575620500_bib18","doi-asserted-by":"crossref","first-page":"e0162303","DOI":"10.1371\/journal.pone.0162303","article-title":"Investigating the effect of ligand amount and injected therapeutic activity: a simulation study for 177Lu-labeled PSMA-targeting peptides","volume":"11","author":"Kletting","year":"2016","journal-title":"PLoS One"},{"key":"2026031614575620500_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2967\/jnumed.115.164699","article-title":"Optimized peptide amount and activity for 90Y-labeled DOTATATE therapy","volume":"57","author":"Kletting","year":"2016","journal-title":"J Nucl Med"},{"key":"2026031614575620500_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2967\/jnumed.118.210377","article-title":"Modeling and predicting tumor response in radioligand therapy","volume":"60","author":"Kletting","year":"2019","journal-title":"J Nucl Med"},{"key":"2026031614575620500_bib21","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/pharmaceutics13122132","article-title":"A physiologically based pharmacokinetic model for in vivo alpha particle generators targeting neuroendocrine tumors in mice","volume":"13","author":"Zaid","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026031614575620500_bib22","doi-asserted-by":"crossref","first-page":"15966","DOI":"10.3390\/ijms232415966","article-title":"Mathematical model for evaluation of tumor response in targeted radionuclide therapy with 211At using implanted mouse tumor","volume":"23","author":"Yonekura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026031614575620500_bib23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/0008-5472.CAN-19-2553","article-title":"Mathematical modeling of preclinical alpha-emitter radiopharmaceutical therapy","volume":"80","author":"Karimian","year":"2020","journal-title":"Cancer Res"},{"key":"2026031614575620500_bib24","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.3390\/cancers13205171","article-title":"A mathematical modeling approach for targeted radionuclide and chimeric antigen receptor T cell combination therapy","volume":"13","author":"Adhikarla","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026031614575620500_bib25","doi-asserted-by":"crossref","first-page":"1358478","DOI":"10.3389\/fimmu.2024.1358478","article-title":"Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy","volume":"15","author":"Adhikarla","year":"2024","journal-title":"Front Immunol"},{"key":"2026031614575620500_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-emitters for radiotherapy: from basic radiochemistry to clinical studies\u2014part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"key":"2026031614575620500_bib27","doi-asserted-by":"crossref","first-page":"e1486948","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"Ghose","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026031614575620500_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.bmt.1702087","article-title":"Assessing permeability alterations of the blood\u2013bone marrow barrier due to total body irradiation: in vivo quantification with contrast enhanced magnetic resonance imaging","volume":"25","author":"Daldrup-Link","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2026031614575620500_bib29","first-page":"358","article-title":"Therapeutic radionuclides: biophysical and radiobiologic principles","volume-title":"Semininars in nuclear medicine","author":"Kassis","year":"2008"},{"key":"2026031614575620500_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41181-021-00149-6","article-title":"EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality","volume":"6","author":"Luurtsema","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"key":"2026031614575620500_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.radonc.2004.09.008","article-title":"The centenary of the discovery of the Bragg peak","volume":"73","author":"Brown","year":"2004","journal-title":"Radiother Oncol"},{"key":"2026031614575620500_bib32","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/trf.17137","article-title":"Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping","volume":"62","author":"Chami","year":"2022","journal-title":"Transfusion"},{"key":"2026031614575620500_bib33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1080\/19420862.2015.1043503","article-title":"High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice","volume":"7","author":"Kelly","year":"2015","journal-title":"MAbs"},{"key":"2026031614575620500_bib34","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"key":"2026031614575620500_bib35","first-page":"272","article-title":"The morphology of myeloma cells changes with progression of the disease","volume":"17","author":"Wajs","year":"2013","journal-title":"Contemp Oncol (Pozn)"},{"key":"2026031614575620500_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","volume":"35","author":"Garc\u00eda-Guerrero","year":"2021","journal-title":"Leukemia"},{"key":"2026031614575620500_bib37","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1007\/s10238-023-01124-y","article-title":"Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs","volume":"23","author":"Liu","year":"2023","journal-title":"Clin Exp Med"},{"key":"2026031614575620500_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1874471011104040306","article-title":"Actinium-225 in targeted alpha-particle therapeutic applications","volume":"4","author":"Scheinberg","year":"2011","journal-title":"Curr Radiopharm"},{"key":"2026031614575620500_bib39","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2009-2336","article-title":"Bone acquisition in healthy young females is reciprocally related to marrow adiposity","volume":"95","author":"Di Iorgi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031614575620500_bib40","doi-asserted-by":"crossref","DOI":"10.1201\/9780429490606","volume-title":"Basic clinical radiobiology","author":"Joiner","year":"2018"},{"key":"2026031614575620500_bib41","doi-asserted-by":"crossref","first-page":"111371","DOI":"10.1016\/j.jtbi.2022.111371","article-title":"Optimization of antitumor radiotherapy fractionation via mathematical modeling with account of 4 R[R8S2Q1M7]s of radiobiology","volume":"558","author":"Kuznetsov","year":"2023","journal-title":"J Theor Biol"},{"key":"2026031614575620500_bib42","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential future direction of measurable residual disease evaluation in multiple myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"key":"2026031614575620500_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-01-481291","article-title":"Pursuing the curative blueprint for early myeloma","volume":"122","author":"Roschewski","year":"2013","journal-title":"Blood"},{"key":"2026031614575620500_bib44","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","article-title":"Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"2026031614575620500_bib45","article-title":"Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)","author":"Scheuher","year":"2023  3","journal-title":"J Pharmacokinet pharmacodynamics"},{"key":"2026031614575620500_bib46","doi-asserted-by":"crossref","first-page":"763686","DOI":"10.3389\/fchem.2021.763686","article-title":"Rapid monitoring of vancomycin concentration in serum using europium (III) chelate nanoparticle-based lateral flow immunoassay","volume":"9","author":"Bian","year":"2021","journal-title":"Front Chem"},{"key":"2026031614575620500_bib47","doi-asserted-by":"crossref","first-page":"114189","DOI":"10.1016\/j.bios.2022.114189","article-title":"Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases","volume":"208","author":"Ordutowski","year":"2022","journal-title":"Biosens Bioelectron"},{"key":"2026031614575620500_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2967\/jnumed.120.243394","article-title":"TAG-72\u2013targeted \u03b1-radionuclide therapy of ovarian cancer using 225Ac-labeled DOTAylated-huCC49 antibody","volume":"62","author":"Minnix","year":"2021","journal-title":"J Nucl Med"},{"key":"2026031614575620500_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-019-0391-1","article-title":"An agent-based systems pharmacology model of the antibody-drug conjugate kadcyla to predict efficacy of different dosing regimens","volume":"22","author":"Menezes","year":"2020","journal-title":"AAPS J"},{"key":"2026031614575620500_bib50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.121.000503","article-title":"Simulating the selection of resistant cells with bystander killing and antibody coadministration in heterogeneous human epidermal growth factor receptor 2\u2013positive tumors","volume":"50","author":"Menezes","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"2026031614575620500_bib51","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-019-04673-1","article-title":"The radiosensitizer onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts","volume":"47","author":"Lundsten","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0306\/3512363\/crc-24-0306.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/11\/2955\/3517790\/crc-24-0306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/11\/2955\/3517790\/crc-24-0306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:58:15Z","timestamp":1773687495000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/11\/2955\/750019\/Mathematical-Modeling-Unveils-Optimization"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0306","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27723370","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727966","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723451","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723394","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762857","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723475","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728032","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723403","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762881","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723427","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762917","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727969","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723391","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723472","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723400","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762878","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723367","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762854","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723448","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762830","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723424","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728005","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727993","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762827","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723421","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723388","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762875","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723469","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723445","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727984","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727960","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728026","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728002","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727987","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723385","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762848","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723466","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762824","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723442","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762896","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762872","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762902","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723418","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728047","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728023","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727978","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727954","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723382","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762869","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762845","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723463","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762821","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723415","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728044","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728020","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762893","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723439","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762905","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727957","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762818","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723484","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723460","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762866","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723436","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723379","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728041","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723412","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762890","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762908","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728017","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727981","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727948","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723481","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723376","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723433","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762887","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762863","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723457","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762911","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727996","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728038","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723409","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727972","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728014","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727999","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723373","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762836","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723454","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723397","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723430","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728011","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762884","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762860","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762914","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27723406","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727975","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727951","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728059","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728035","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7539499","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2024.05.22.595377","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}